SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Frédéric Chopin

PatientFrédéric Chopin
Date of birth1998-03-01
IdentifiersMRN HR-NI020-SYN; SSN (made up) 000-20-8845
Document date2026-05-15
AuthorMatthias Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End of the eight-week intensive phase. [S]

History of Present Illness

Mr. Chopin completed the 56 doses of the intensive phase yesterday, all observed by video within eight weeks, and pyrazinamide has stopped; from today he takes rifapentine, moxifloxacin, isoniazid, and pyridoxine for nine more weeks. The isolate is susceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin. The cultures from the third week show no growth at six weeks. His cough has gone except for a little phlegm on waking, and he has gained 3.5 kg since diagnosis. He has no tendon pain, tingling, yellowing, or rash. He is teaching twelve students a week and has told them about his illness; none has left. The health department tells him the investigation of his contacts is going well, without giving him details. [S]

ElementDetail
Treatment56 of 56 intensive-phase doses observed; continuation phase from today
SusceptibilitySusceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin
CulturesThird-week cultures negative at six weeks
Weight52.0 kg, up 3.5 kg

Review of Systems

SystemResultFinding
RespiratoryPositiveA little phlegm on waking; no cough during the day; no blood
ConstitutionalNegativeNo fever or night sweats; appetite good
MusculoskeletalNegativeNo tendon pain
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood good; PHQ-9 4; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses)Oral route2026-03-20 to 2026-07-16completedS
Moxifloxacin 400 mg tablet, one tablet daily400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours afterOral route2026-03-20 to 2026-07-16completedS
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeksOral route2026-03-20 to 2026-07-16completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg)Oral route2026-03-20 to 2026-05-14completedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-03-20 to 2026-07-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-15Body height170cmS
2026-05-15Body weight52kgS
2026-05-15Body mass index (BMI) [Ratio]18kg/m2S
2026-05-15Systolic blood pressure108mm[Hg]S
2026-05-15Diastolic blood pressure68mm[Hg]S
2026-05-15Heart rate78/minS
2026-05-15Respiratory rate16/minS
2026-05-15Body temperature36.8CelS
2026-05-15Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-15Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L7-56 U/LNormalS
2026-05-15Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L10-40 U/LNormalS
2026-05-15Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-05-15Hemoglobin [Mass/volume] in Blood13g/dL13.2-16.6 g/dLLowS
2026-05-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-05-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 52.0 kg
EyesNo icterus
RespiratoryClear apart from a few fine crackles at the right apex
MusculoskeletalTendons non-tender
NeurologicalNormal sensation in the fingers and feet

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and cultureresolvedconfirmed R04.2S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit.
Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic.
Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dLactiveconfirmed E44.0S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsEvery visitCompleted todayMorning phlegm only
ExaminationWeight, with the pyrazinamide dose checked against the weight bandMonthlyCompleted today52.0 kg; pyrazinamide finished within its band
Medication safetyAdverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluidsEvery visitCompleted todayNone
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin)Completed todayALT 29, AST 27 U/L, bilirubin 0.6 mg/dL, all normal
LaboratoryHemoglobinWhen low at baselineCompleted today13.0 g/dL, up from 12.1; anemia of inflammation resolving
LaboratoryPhenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin)At baselineCompleted todaySusceptible to rifampin, isoniazid, pyrazinamide, and moxifloxacin
LaboratorySputum acid-fast smear and cultureBaseline, then monthly until two consecutive cultures are negativeCompleted todayThird-week cultures: no growth at six weeks (first negative culture)
LaboratoryTwo-month sputum cultureAt the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testingCompleted todaySmear negative today; culture sent
ImagingChest X-rayBaseline; at two months only if baseline cultures were negative; end of treatment optionalNot indicatedNot needed at two months, because the baseline cultures were positive
Medication safetyDoses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months)Every visitCompleted today56 doses in 56 days, within the 70-day limit
ReferralContact investigation (students, friends, close contacts)Led by the health department from diagnosisReferredContinuing with the health department; no results in his record
SurveyDepression screen (PHQ-9)At diagnosis, at two months, and at the end of treatmentCompleted today4, item 9 scored 0
Self-managementNutrition: dietitian, intake, supplement drinksEvery visit until weight is restoredCompleted todaySupplements continue; eating well
ReferralInfectious diseases reviewAt diagnosis, at two months, and at the end of treatmentCompleted todayResults reviewed by message today

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: End-of-treatment visit after the 119th dose. Call the same day for hepatitis symptoms, tendon pain, or a returning cough. Next scheduled visit 2026-07-21: end-of-treatment review after 119 doses. [S]